Talzenna set for Lynparza tussle in prostate cancer

5 October 2022

US pharma giant Pfizer (NYSE: PFE) has presented promising results on its PARP inhibitor Talzenna (talazoparib) alongside Xtandi (enzalutamide) in metastatic castration-resistant prostate cancer (mCRPC).

The data suggests that a battle with AstraZeneca (LSE: AZN) and Merck & Co’s (NYSE: MRK) PARP inhibitor Lynparza (olaparib) could be on the horizon in this competitive indication.

"Talzenna in prostate cancer may become the next potential blockbuster opportunity in our leading Pfizer Oncology portfolio"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK